Publications by authors named "T Smeal"
Purpose: This phase II study evaluated the efficacy and tolerability of onvansertib, a polo-like kinase 1 (PLK1) inhibitor, in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI) + bevacizumab for the second-line treatment of -mutant metastatic colorectal cancer (mCRC).
Patients And Methods: This multicenter, open-label, single-arm study enrolled patients with -mutated mCRC previously treated with oxaliplatin and fluorouracil with or without bevacizumab. Patients received onvansertib (15 mg/m once daily on days 1-5 and 15-19 of a 28-day cycle) and FOLFIRI + bevacizumab (days 1 and 15).
Article Synopsis
- Endocrine therapy combined with CDK4/6 inhibitors is the standard first-line treatment for hormone receptor-positive metastatic breast cancer, but resistance can develop, requiring alternative therapies like alpelisib.
- Researchers explored the effects of combining alpelisib with the PLK1 inhibitor onvansertib in preclinical models to improve treatment outcomes for patients with resistant -mutant HR+ breast cancer.
- Results showed that the combination significantly inhibited cancer cell growth and enhanced apoptosis in resistant models, suggesting it could be an effective new treatment strategy that needs further clinical testing.
Pediatric end-of-life (EOL) care at home is often provided by community palliative care (CPC) nurses who do not specialize in pediatrics. This study aimed to better understand the challenges CPC nurses face when providing EOL care to children at home. A total of 52 CPC nurses across New South Wales (NSW), Australia, participated in an online survey about their training, attitudes, and experiences regarding the provision of home-based pediatric EOL care.
View Article and Find Full Text PDFPurpose: Onvansertib is a highly specific inhibitor of polo-like kinase 1 (PLK1), with demonstrated safety in solid tumors. We evaluated, preclinically and clinically, the potential of onvansertib in combination with chemotherapy as a therapeutic option for KRAS-mutant colorectal cancer.
Patients And Methods: Preclinical activity of onvansertib was assessed (i) in vitro in KRAS wild-type and -mutant isogenic colorectal cancer cells and (ii) in vivo, in combination with irinotecan, in a KRAS-mutant xenograft model.